MTCH2 exhibits both inhibitory and promotive roles in different tumors, suggesting that it regulates distinct tumor‐related molecules or pathways.[22, 23, 24, 25] In cervical carcinoma, loss of MTCH2 increased tumor cell proliferation by suppressing apoptosis.[23] MiR‐135b/MTCH2 inhibition promoted the progression of erbB2‐driven mammary carcinomas.[24] Conversely, silencing of MTCH2 decreased cell growth in ovarian cancer by downregulation of AIMP2 expression levels.[41] In glioma cells, Yuan et al. Here, ERBB2 is linked to ovarian carcinoma.